Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 22, 2007SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of additional data from the SPIRIT FIRST, II and III...
-
May 22, 2007Study highlights importance of antiplatelet therapy compliance
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of more than 7,000 patients from its ARRIVE...
-
May 22, 2007Trial results report no new stent thrombosis after two years in high-risk patient population
Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS VI clinical trial. The data...
-
May 18, 2007Group supports call for limiting greenhouse gas emissions
Boston Scientific Corporation (NYSE: BSX) today announced that it has joined the U.S. Climate Action Partnership (USCAP). USCAP was formed as a...
-
May 18, 2007Company anticipates broad range of clinical results on endoscopic technologies
Boston Scientific Corporation (NYSE: BSX) today announced that results from several clinical studies designed to determine the safety and efficacy...
-
May 17, 2007Single-operator system allows unprecedented visual access to bile duct
Boston Scientific Corporation (NYSE: BSX) today announced worldwide commercial availability of its SpyGlass™ Direct Visualization System for...
-
May 15, 2007Company to release broad range of clinical data on leading drug-eluting stent portfolio
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual Paris...
-
May 14, 2007More than 23,000 patients now enrolled in TAXUS OLYMPIA registry
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the European and Intercontinental phases (II and III)...
-
May 10, 2007New data provide support for minimally invasive treatment of atrial fibrillation (AF)(1)
Boston Scientific Corporation (NYSE: BSX) today commented on data released on May 9th at the American Association for Thoracic Surgery (AATS)...
-
May 9, 2007
Boston Scientific Corporation (NYSE: BSX) today released data reflecting clinical event notification statistics from the first 10,000 patients(1)...
-
May 8, 2007Reimbursement granted by National Health Insurance System
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS® Express2™ paclitaxel-eluting coronary stent system in Japan....
-
May 3, 2007RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its RENAISSANCE study, which was designed to evaluate...
-
May 1, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice...
-
Apr 26, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its SYNTAX clinical trial. SYNTAX is the first trial...
-
Apr 24, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being...
-
Apr 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2007, as well as guidance for...
-
Apr 17, 2007Product provides enhanced control for accessing desired vessel location
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of the ACUITY® Steerable left...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2007...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that the Company has resolved the deficiencies in the warning letter issued by the U.S....
-
Apr 3, 2007
Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Apr 2, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its MAPS™ clinical trial. The MAPS trial (Matrix And...
-
Mar 26, 2007BTK CHILL study demonstrates high rate of limb protection at one year
Boston Scientific Corporation (NYSE: BSX) today announced excellent one-year results from its Below-The-Knee (BTK) CHILL study,...
-
Mar 25, 2007
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from the TAXUS V In-Stent Restenosis (ISR) trial,...
-
Mar 25, 2007Two-year review of TAXUS Stent safety data presented at ACC
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its ARRIVE 1 registry and the combined one-year...
-
Mar 24, 2007Results reaffirm strength of Boston Scientific's dual drug-eluting stent program
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of the pivotal SPIRIT III clinical trial, which reaffirmed...
-
Mar 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced a program designed to improve patient compliance with physician-prescribed anti-platelet...
-
Mar 22, 2007Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced regulatory approval and market launch in Japan for its VITALITY™ DR implantable...
-
Mar 20, 2007Company to host analyst meeting and symposium on drug-eluting stents
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual...
-
Mar 13, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Lehman Brothers Health Care Conference, which is being held March 19...
-
Mar 12, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that its Board of Directors has authorized management to explore an initial public...
-
Mar 8, 2007
Boston Scientific Corporation (NYSE: BSX) today announced several enhancements related to the governance of the company. "Boston Scientific is...
-
Mar 6, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen Health Care Conference, which is being held March 12 - 15 in...
-
Mar 5, 2007
Boston Scientific Corporation (NYSE: BSX) released the following statement today in response to a request for information relating to its TAXUS®...
-
Feb 28, 2007Campaign spokesperson - a Formula race car driver, amputee, and chronic pain patient - to promote public awareness
Boston Scientific Corporation (NYSE: BSX) announced today the launch of its Neuromodulation Group's Race Against Pain public outreach campaign to...
-
Feb 12, 2007
Boston Scientific Corporation (NYSE: BSX) today commented on results from a Swedish registry assessing the long-term outcomes of drug-eluting...
-
Feb 12, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the online release of several important articles scheduled for publication in the March...
-
Feb 5, 2007DES patients have significantly lower rates of death, heart attack and re-intervention than BMS patients
Boston Scientific Corporation (NYSE: BSX) today welcomed data from a study showing that drug- eluting stents (DES) have substantially lower rates of...
-
Feb 2, 2007
Boston Scientific Corporation (NYSE: BSX) today commented on a proposed National Coverage Determination (NCD) released by the Centers for Medicare...
-
Feb 1, 2007Company provides guidance for first quarter 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2006, as well as...
-
Jan 31, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 29, 2007Longer balloon gives physicians broader treatment options in peripheral artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand its...
-
Jan 25, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 18, 2007New U.S. shelf life is longer than any competing drug-eluting stent product
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of...
-
Jan 17, 2007Court Orders Injunction and Damages
Boston Scientific Corporation (NYSE: BSX) announced today that it and Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) won a patent...
-
Jan 16, 2007
Boston Scientific Corporation (NYSE: BSX) commented on a decision today by the U.K. Court of Appeal that affirmed an earlier ruling by a lower...
-
Jan 12, 2007Lower rates of re-intervention and major adverse events reported for the TAXUS Stent in study of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of an independent study demonstrating that Boston Scientific's TAXUS®...
-
Jan 11, 2007Boston Scientific only company to offer two distinct drug-eluting stent platforms
Boston Scientific Corporation (NYSE:BSX) today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting...
-
Jan 10, 2007
Boston Scientific Corporation (NYSE: BSX) today announced preliminary, unaudited net sales for its fourth quarter and full year ended December 31,...
-
Jan 8, 2007Plan to increase innovation, productivity and competitiveness
Boston Scientific Corporation (NYSE: BSX) today announced a plan to reallocate its cardiac rhythm management (CRM) research and development...
-
Jan 4, 2007Acquisition demonstrates Company's commitment to leadership in treating carotid artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has acquired EndoTex Interventional Systems, Inc. The acquisition follows the Food and...